© 2026 Aureon Bioscience
AOD9604 - Wholesale
Sale price
$50.00
Regular price
$100.00
Skip to product information
AOD9604 - Wholesale
Overview
AOD9604 is a synthetic peptide fragment derived from the C-terminal domain of human growth hormone (hGH), comprising amino acid residues 176–191 with a tyrosine substitution at the N-terminus. Originally developed by Metabolic Pharmaceuticals as a potential anti-obesity agent, it was designed to replicate the lipolytic properties of hGH without activating the growth hormone receptor or elevating IGF-1 levels.
Mechanism of Action
AOD9604 is proposed to stimulate lipolysis and inhibit lipogenesis through mechanisms involving upregulation of beta-3 adrenergic receptor (β3-AR) expression in adipocytes, modulation of hormone-sensitive lipase (HSL), and inhibition of acetyl-CoA carboxylase. Unlike intact hGH, it does not meaningfully affect insulin sensitivity or glucose metabolism at research doses.
Research and Off-Label Applications
AOD9604 has been investigated for reduction of visceral and subcutaneous adipose tissue, fat oxidation and energy expenditure, cartilage and tissue repair, and as a potential adjunct in metabolic syndrome research. Human clinical trials have produced mixed results, with one 12-week randomized trial reporting approximately 1.8 kg greater fat loss versus placebo. Animal models have demonstrated more pronounced lipolytic effects.
Administration
Typically administered via subcutaneous injection. Research protocols commonly utilize doses of 250–500 mcg per day, often in the morning to align with natural fat metabolism cycles. Higher doses have not demonstrated significantly greater outcomes in clinical data.
Regulatory Status
AOD9604 is not FDA-approved for any indication. It is classified as a prescription-only substance by Australia's Therapeutic Goods Administration (TGA) and is prohibited in competitive sport under WADA regulations. Clinical development was halted in 2007.
Potential Adverse Effects
Generally well tolerated in available research. Reported effects include mild injection site reactions. No significant impact on insulin sensitivity has been reported at research doses.
Pharmacokinetics
Plasma half-life is approximately 4 minutes following intravenous administration; oral forms demonstrate slower absorption kinetics. Sequential N-terminal amino acid truncation is the primary degradation pathway.
Properties
1. Basic Information
2. Structural Properties Peptide Nature: Linear 16-amino acid peptide with internal disulfide bond between Cys182 and Cys189 forming a constrained loop region; N-terminal tyrosine substitution distinguishes it from native hGH fragment
Secondary Structure: Adopts a constrained loop conformation stabilized by the intramolecular disulfide bridge; no significant α-helical or β-sheet content under physiological conditions
Hydrophobicity: Moderately hydrophobic; phenylalanine and isoleucine residues contribute to hydrophobic character; overall balanced polarity profile
Charge: Net positive charge at physiological pH due to arginine residues (Arg178, Arg183)
3. Solubility
4. Stability Thermal Stability: Sensitive to elevated temperatures; the disulfide bond is susceptible to reduction under strongly reducing conditions
Proteolytic Stability: Moderate stability in plasma; susceptible to N-terminal exopeptidase activity; plasma half-life approximately 4 minutes (IV); subcutaneous administration produces slower absorption kinetics
Storage: Store lyophilized at −20°C protected from light and moisture; reconstituted solution stable up to 14 days at 2–8°C; avoid repeated freeze-thaw cycles
5. Chemical Reactivity Intramolecular disulfide bond between Cys182 and Cys189 is essential for maintaining bioactive conformation; reduction abolishes reported lipolytic activity in experimental models
N-terminal tyrosine substitution confers enhanced stability relative to native hGH 176–191 fragment under experimental conditions
Peptide bonds are stable at neutral pH; susceptible to acid or base hydrolysis under extreme conditions
No fatty acid conjugation; peptide relies on cyclic disulfide constraint rather than albumin binding for activity profile
Methionine residues absent; oxidative degradation risk profile is low relative to methionine-containing peptides
6. Other Properties
- Name: AOD9604 (Advanced Obesity Drug 9604)
- Type: Synthetic C-terminal hGH fragment peptide
- Length: 16 amino acids (residues 176–191 of human growth hormone)
- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge Cys182–Cys189)
- Molecular Weight: ~1,817 Da
- Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
2. Structural Properties Peptide Nature: Linear 16-amino acid peptide with internal disulfide bond between Cys182 and Cys189 forming a constrained loop region; N-terminal tyrosine substitution distinguishes it from native hGH fragment
Secondary Structure: Adopts a constrained loop conformation stabilized by the intramolecular disulfide bridge; no significant α-helical or β-sheet content under physiological conditions
Hydrophobicity: Moderately hydrophobic; phenylalanine and isoleucine residues contribute to hydrophobic character; overall balanced polarity profile
Charge: Net positive charge at physiological pH due to arginine residues (Arg178, Arg183)
3. Solubility
- Soluble in sterile water and aqueous buffers; optimal solubility at pH 5.5–7.0
- Reconstitution recommended in bacteriostatic water or sterile saline for research use
- Supplied as lyophilized white to off-white powder
4. Stability Thermal Stability: Sensitive to elevated temperatures; the disulfide bond is susceptible to reduction under strongly reducing conditions
Proteolytic Stability: Moderate stability in plasma; susceptible to N-terminal exopeptidase activity; plasma half-life approximately 4 minutes (IV); subcutaneous administration produces slower absorption kinetics
Storage: Store lyophilized at −20°C protected from light and moisture; reconstituted solution stable up to 14 days at 2–8°C; avoid repeated freeze-thaw cycles
5. Chemical Reactivity Intramolecular disulfide bond between Cys182 and Cys189 is essential for maintaining bioactive conformation; reduction abolishes reported lipolytic activity in experimental models
N-terminal tyrosine substitution confers enhanced stability relative to native hGH 176–191 fragment under experimental conditions
Peptide bonds are stable at neutral pH; susceptible to acid or base hydrolysis under extreme conditions
No fatty acid conjugation; peptide relies on cyclic disulfide constraint rather than albumin binding for activity profile
Methionine residues absent; oxidative degradation risk profile is low relative to methionine-containing peptides
6. Other Properties
- Selective lipolytic activity: Reported to stimulate lipolysis and inhibit lipogenesis in adipocyte models without activating the full-length GH receptor or elevating IGF-1
- IGF-1 independence: Structural truncation to C-terminal region is described as dissociating adipocyte-directed activity from somatotropic axis engagement in preclinical literature
- Disulfide-dependent bioactivity: Reduced (linear) form of AOD9604 has been reported as significantly less active than the oxidized (disulfide-intact) form in experimental adipocyte assays
- Regulatory history: Evaluated in Phase II and Phase III clinical trials for obesity; clinical development discontinued in 2007; classified as Generally Recognized as Safe (GRAS) by the FDA in 2014 in specific oral formulation contexts
Description
AOD9604 is a synthetic research peptide and has been described in the scientific literature as a C-terminal fragment analog of human growth hormone (hGH), comprising residues 176–191 with a tyrosine substitution at the N-terminus. Publications referencing AOD9604 discuss it in the context of adipocyte signaling, lipolytic pathway pharmacology, and metabolic regulation within experimental systems.
Reports involving AOD9604 describe its proposed interactions with adipocyte receptor systems and associated downstream signaling properties under defined experimental conditions. Observations of beta-3 adrenergic receptor expression modulation, hormone-sensitive lipase activity, and lipogenesis-associated signaling components are limited to non-clinical and early-phase clinical research settings and are reported as descriptive findings within cellular, animal model, and controlled human studies.
All references to AOD9604 are confined to mechanistic and observational research contexts and do not extend beyond laboratory-based and clinical investigation.
In the scientific literature, AOD9604 has been referenced in non-clinical and clinical research involving adipocyte biology, metabolic signaling assays, and controlled human trials. These publications describe experimental contexts in which molecular interactions, lipolytic signaling components, and pathway-associated metabolic markers were observed and recorded.
Reported research contexts include examination of:
- Beta-3 adrenergic receptor expression dynamics and adipocyte signaling patterns in experimental models
- Hormone-sensitive lipase (HSL) modulation and lipogenic pathway components observed in research settings
- Acetyl-CoA carboxylase inhibition markers evaluated under experimental conditions
- Visceral and subcutaneous adipose tissue metabolism assessed in preclinical and early clinical contexts
- Comparative receptor interaction profiles relative to intact human growth hormone in experimental systems
All reported applications are confined to descriptive investigation within controlled laboratory and clinical research environments.
Mechanistic discussions in preclinical publications describe AOD9604 as a hGH-derived fragment in which structural truncation to the C-terminal region is described as dissociating lipolytic activity from IGF-1 axis engagement and growth hormone receptor activation. The tyrosine substitution at the N-terminus is described as contributing to structural stability within experimental systems. These descriptions are limited to molecular and biochemical observations and do not imply functional outcomes beyond the reported research context.
AOD9604 is supplied as a research-grade peptide material. Identity and composition have been reported as characterized using analytical techniques commonly applied to peptide research materials, including chromatographic and mass spectrometric methods. Individual laboratories determine handling, storage, and analytical verification parameters in accordance with internal research protocols.
COA
Storage
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months. Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
For longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80°C (-112°F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide's stability.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
For longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80°C (-112°F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide's stability.
